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Background: Juvenile idiopathic arthritis is a relatively common chronic disease of childhood, and is associated with
persistent morbidity and extra-articular complications, one of the most common being uveitis. The introduction of
biologic therapies, particularly those blocking the inflammatory mediator tumor necrosis factor-α, provided a new
treatment option for juvenile idiopathic arthritis patients who were refractory to standard therapy such as non-steroidal
anti-inflammatory drugs, corticosteroids and/or methotrexate.
Case presentations: The first case was a 2-year-old girl with juvenile idiopathic arthritis and uveitis who failed to
respond to treatment with anti-inflammatories, low-dose corticosteroids and methotrexate, and had growth retardation.
Adalimumab 24 mg/m2 every 2 weeks and prednisone 0.5 mg/kg/day were added to methotrexate therapy; steroid
tapering and withdrawal started after 1 month. After 2 months the patient showed good control of articular and ocular
manifestations, and she remained in remission for 1 year, receiving adalimumab and methotrexate with no side effects,
and showing significant improvement in growth. Case 2 was a 9-year-old boy with an 8-year history of juvenile
idiopathic arthritis and uveitis that initially responded to infliximab, but relapse occurred after 2 years off therapy. After
switching to adalimumab, and adjusting doses of both adalimumab and methotrexate based on body surface area, the
patient showed good response and corticosteroids were tapered and withdrawn after 6 months; the patient remained
in remission taking adalimumab and methotrexate. The final case was a 5-year-old girl with juvenile idiopathic arthritis
for whom adalimumab was added to methotrexate therapy after three flares of uveitis. The patient had two subsequent
episodes of uveitis that responded well to local therapy, but was then free of both juvenile idiopathic arthritis and uveitis
symptoms, allowing methotrexate and then adalimumab to be stopped; the patient remained in drug-free remission.
Conclusion: This report includes the first published case of the use of adalimumab in a child aged <3 years. Our clinical
experience further supports the use of biologic therapy for the management of juvenile idiopathic arthritis and uveitis in
children as young as two years of age.
Keywords: Adalimumab, Juvenile idiopathic arthritis, Children, UveitisBackground
Juvenile idiopathic arthritis (JIA) is defined as arthritis of
unknown etiology with onset prior to 16 years of age that
persists for 6 weeks or longer and is not secondary to any
other conditions [1]. Classification of JIA is based on the
criteria developed by the International League of Associa-
tions for Rheumatology (ILAR) [1,2]. JIA is one of the* Correspondence: latorre_francesco@virgilio.it
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prevalence in the United States (US) and Northern Europe
is estimated to be 7–21 cases per 100,000 of population
[4]. JIA can have an adverse effect on the growth and de-
velopment of joints and bones, often persists into adult-
hood and can result in significant long-term morbidity,
including physical disability [3,5,6]. Factors contributing to
growth suppression in JIA include the degree, extent and
duration of disease activity, age at onset, immobility, sub-
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Figure 1 Case 1 left knee ultrasound. Transverse gray-scale and
color Doppler 12–5 MHz ultrasound image obtained over the medial
aspect of the knee showing abundant synovial pannus filling the
subquadriceps recess as a band of hypoechoic tissue intermingled
with fluid. Marked synovial hyperemia is observed at color Doppler
examination indicating active pannus.
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steroidal anti-inflammatory drugs (NSAIDs), systemic glu-
cocorticoids and/or disease-modifying anti-rheumatic drugs
(DMARDs) such as methotrexate. However, up to 30% of
patients do not respond to treatment [7]. A new era in the
treatment of JIA arrived with the introduction of biologic
therapies, particularly those blocking the inflammatory me-
diator tumor necrosis factor-α (TNF-α) [8]. Approximately
80% of patients with active polyarticular disease, despite
previous use of non-biologic DMARDs, have been shown
to respond to biological drugs, and children treated with
biologic therapy feel better and have less pain [9,10]. Treat-
ment guidelines in the US now recommend switching to
biologic therapy in JIA patients with persistent moderate-
to-severe disease activity, or drug intolerance, after four
months of treatment with standard medical therapy [11].
TNF-α has also been reported to play a role in the patho-
genesis of ocular inflammation, with high levels detected in
the serum and aqueous humor of patients with uveitis
[12-14]. Chronic anterior uveitis is insidious, highly refrac-
tory, bilateral in 80% of patients, often corticosteroid-
dependent, and associated with high rates of medium- and
long-term complications such as posterior synechiae, band
keratopathy, cataract and glaucoma [15,16]. Overall, 20% to
25% of all pediatric uveitis is associated with JIA [17]. An-
terior uveitis is the most frequent extra-articular disease as-
sociated with JIA [15,18,19]. The major risk factors for the
development of uveitis in JIA patients are oligoarticular pat-
tern of arthritis, onset of arthritis before 7 years of age and
antinuclear antibody positivity [18]. In the initial stages of
mild to moderate inflammation, uveitis is entirely asymp-
tomatic. This has led to the current practice of screening all
children with JIA regularly for uveitis. Approximately 12%
to 38% of patients with JIA will develop uveitis in the 7 years
following the onset of arthritis [19]. In 30% to 50% of chil-
dren with JIA-associated uveitis, structural complications
are present at the time of diagnosis [20]. Furthermore,
about 50% to 75% of those with severe uveitis will eventu-
ally develop visual impairment secondary to ocular compli-
cations such as cataract, glaucoma, band keratopathy and
macular pathology [21-23]. Early and aggressive interven-
tion is appropriate to prevent irreversible complications
and preserve visual acuity.
Significant prognosticators of poor visual acuity include
structural changes at presentation, the need for intraocular
surgery, posterior segment inflammation, abnormal intra-
ocular pressure and failure to maintain long-term disease
control as marked by persistent anterior chamber (AC)
cell scores of 1 or higher [20-22,24].
While anti-TNF agents have a significant impact on the
management of JIA, experience on their effects on uveitis
remains limited, particularly in younger patients. The three
cases presented here document the safety and effectiveness
of adalimumab in children with JIA and co-morbid uveitis,one of them being, to our knowledge, the first published
case report of the use of this biological drug in a child
aged <3 years.
Case Presentations
Case 1
A 2-year-old girl presented at hospital with JIA and bilat-
eral chronic uveitis. The onset of articular disease was at
8 months of age and the diagnosis of JIA was made at age
14 months. She had previously been treated with injec-
tions of triamcinolone hexacetonide into her left knee and
left ankle joints, which resulted in temporary disease con-
trol, but arthritis relapsed in the same joints after 3 months
(Figures 1 and 2). The patient had difficulties in walking and
climbing stairs. Anti-inflammatory drugs and low-dose cor-
ticosteroids were initiated without benefit. Two months
later, at age 19 months, subcutaneous methotrexate 15 mg/
m2/week was added. Arthritis improved, but bilateral
chronic anterior uveitis developed after 3 months, despite
ongoing methotrexate treatment. The diagnosis was made
at the regular ocular screening follow-up, because she didn’t
show any ocular symptoms, but at slit-lamp examination
cells in the anterior chamber were present. Uveitis was ini-
tially managed with standard eye care, but several relapses
occurred resulting in the formation of bilateral papilledema.
Brain magnetic resonance imaging was normal. She had
growth retardation (weight 9.8 kg[<3rd percentile], height
76 cm[−3 standard deviations from normal]) (Figure 3).
The patient was started on treatment with adalimumab
24 mg/m2 every 2 weeks in combination with prednisone
Figure 2 Case 1 left ankle ultrasound. Midsagittal 12–5 MHz
ultrasound image over the dorsal ankle shows a distended anterior
joint recess, filled with hypoechoic fluid with active synovial pannus
as marked by color Doppler examination.
Figure 3 Case 1 (age 2 years). Photograph patient with juvenile
idiopathic arthritis with fixed flexion contraction of the left leg for
active knee and ankle joints arthritis (red arrows).
Figure 4 Case 1 left knee ultrasound after treatment. Left knee:
transverse gray-scale 12–5 MHz ultrasound image obtained over the
medial aspect of the knee showing normal aspect of the joint
without fluid or synovial pannus into the subquadriceps recess.
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tapering; methotrexate was continued at the same dose.
Two months later, both articular and ocular manifesta-
tions were well controlled, papilledema had resolved and
corticosteroid treatment was stopped (Figures 4 and 5).
One year later the patient was still in remission receiving
adalimumab and methotrexate, without any side effects.
Her growth rate significantly improved in the absence of
corticosteroid treatment and with no disease relapses
(weight 15 kg[10th percentile], height 100 cm[−1 standard
deviation from normal]) (Figure 6). After two years,
methotrexate dose reduction was undertaken.
Case 2
A boy aged 9 years and 4 months was admitted to hospital
in June 2012 with oligo-articular extended-onset JIA and
associated chronic bilateral uveitis with posterior syne-
chiae. Immune serology was positive for antinuclear anti-
bodies (ANA) and human lymphocyte antigen (HLA) B27,
while rheumatoid factor (RF) was negative. Age at disease
onset was 1 year 9 months, when the patient presented
with bilateral anterior uveitis with eyes redness and head-
ache, diagnosed with slit-lamp that showed cells in the an-
terior chamber. He was treated with steroid eye drops and
mydriatics. At the same time, he presented arthritis of the
left ankle, progressing into oligoarticular extended form
with arthritis of the knees, left elbow, left shoulder, left
wrist and the small joints of the hands and feet. The pa-
tient was treated with injections of triamcinolone hexace-
tonide1 mg/kg into the left ankle and both knees.
Figure 5 Case 1 left ankle ultrasound after treatment.
Midsagittal12 − 5 MHz US image over the dorsal ankle showing
normal joint recess, without hypoechoic fluid or synovial pannus.
Figure 6 Case 1 after 2 years of ongoing adalimumab
treatment. Photograph showing patient in remission at 4 years of age.
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flare and was started on oral prednisone 1 mg/kg/day and
subcutaneous methotrexate 10 mg/m2/week. Between No-
vember 2008 and July 2011 the patient was treated with
infliximab, and had a good response for 2 years, but then
experienced a number of relapses of uveitis. Therefore, in
August 2011, he was switched to adalimumab 20 mg every
2 weeks.
On his most recent presentation, the patient was admit-
ted to hospital with relapsed uveitis and arthritis of the right
knee (limited range of motion and pain) while being treated
with prednisone 0.5 mg/kg/day, adalimumab 20 mg every
2 weeks and methotrexate 10 mg/week. In October 2012,
the dosages of both adalimumab and methotrexate were
progressively increased based on body surface area (m2):
adalimumb to 25 mg every 2 weeks (specific paediatric for-
mulation 24 mg/m2 every 2 weeks) and methotrexate to
15 mg/week(15 mg/m2/week). The corticosteroid dosage
was progressively tapered to withdrawal over the next
6 months without any flare of uveitis. The patient has
maintained clinical remission for the last 6 months receiv-
ing ongoing therapy with adalimumab 24 mg/m2 every
2 weeks, based on surface area using specific pediatric for-
mulation, and with MTX 15 mg/m2/week.
Case 3
A 5-year-old girl was referred in August 2008 for manage-
ment of arthritis. The patient had severe swelling and lim-
ited range of motion in the right ankle, slight swelling and
slight effusion in the right knee with full range of motion,
and slight swelling of the right wrist and the fourth
metacarpo-phalangeal joint of the left hand. Physical
examination was otherwise unremarkable. Laboratory
tests showed high ESR (64 mm/h) and ANA positivity,
with a titer of 1:640 and homogeneous pattern. Though in
the absence of ocular symptoms, eye evaluation with slit-
lamp examination was positive for signs of iridociclitis,
showing cells in the anterior chamber with initial bandkeratopathy and sinechiae; visual acuity was normal. A
diagnosis of ANA positive-JIA was made and naproxen,
corticosteroid eye drops and mydriatics were prescribed.
Three weeks later the patient showed a partial response to
treatment, and slit-lamp examination showed no signs of
active uveitis but persistent band keratopathy and sinechie.
Subcutaneous methotrexate 12.5 mg/m2/week was then
initiated.
In October 2008 physical exam revealed severe swelling
of the right wrist with limitation in the range of motion,
and swelling of the fourth left metacarpo-phalangeal joint.
The diagnosis of polyarticular JIA was confirmed, NSAIDS
were stopped and prednisone 1 mg/kg/day was started then
rapidly tapered over the next two weeks. Two months later
the patient showed a good response with an unremarkable
physical examination and no active uveitis. From May 2010
to September 2010 the patient experienced three flares of
uveitis that were treated with local corticosteroids and myd-
riatics; physical exam on these occasions revealed no signs
of arthritis and laboratory findings were normal. However,
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to add subcutaneous adalimumab 24 mg/m2 every 2 weeks
to the ongoing therapy with methotrexate. After two other
episodes of uveitis (November 2010 and March 2011) that
responded well to local therapy, the patient has shown no
signs of either arthritis or uveitis during regular follow-up
since March 2011. Methotrexate therapy was tapered and
then stopped in December 2012, and adalimumab was con-
tinued. In February 2013 adalimumab was stopped and the
patient has remained free of arthritis and uveitis since then.
Both methotrexate and adalimumab were well tolerated,
with no clinical or laboratory signs of adverse effects.
Discussion
We have described three children with JIA and uveitis who
responded well to adalimumab therapy. All were treated
with the pediatric formulation of adalimumab with dosing
based on body surface area. The main evidence for use of
adalimumab in children with JIA has come from a random-
ized, controlled trial in patients with polyarticular disease
[25]. Other anti-TNF agents have also shown benefits in
these patients [26,27].
A critical issue in the management of JIA is co-morbid
uveitis that is often refractory to conventional DMARDs
and require high dose glucocorticoids. Recently, anti-TNF
agents, including infliximab and adalimumab, have shown
to be very effective in JIA patients who present with re-
fractory uveitis [28-38].
Although an indirect comparison showed that adali-
mumab and infliximab were equally efficacious in terms
of response to treatment and for the prevention of dis-
ease flare, adalimumab appeared to be more effective
and better tolerated than infliximab, as evidenced by re-
cent data from the National Italian Registry of child-
hood chronic uveitis associated with JIA and from other
published experiences [38-40]. Moreover, an open-label
prospective, comparative, multicenter cohort study of
childhood noninfectious chronic uveitis, with 22 chil-
dren with uveitis associated with JIA (12 treated with
Adalimumab and 10 with Infliximab), confirmed that
over 3 years of treatment, adalimumab is more efficacious
than infliximab in maintaining remission of chronic child-
hood uveitis [36]. Recently, Simonini et al., even if limited
to a relatively small group, showed a better efficacy of Ada-
limumab when used as first anti- TNF alpha treatment in
childhood chronic uveitis [37].
In contrast, etanercept has been reported not to halt
the onset of uveitis or to be more effective than placebo
[41,42], and some reports of new-onset uveitis associated
with etanercept use in JIA have been published [43].
In fact, infliximab has been shown to be better than eta-
nercept in children with ankylosing spondylitis and anterior
uveitis and, in patients with JIA and uveitis, adalimumab
showed better outcome than etanercept [28,44]. For thesereasons, etanercept is not considered to be effective in
treating intraocular inflammation [45].
We hypothesize that these monoclonal antibodies (adali-
mumab and infliximab) would be more effective in sup-
pressing ocular inflammation than etanercept, which is a
synthetic receptor for TNF-α and does not act against cell-
bound TNF.
We also suppose that adalimumab would provide a su-
perior response than infliximab in maintaining remis-
sion, because it binds to TNF-α on the cell surface and
not just in the circulation.
For the reasons mentioned above, adalimumab was
chosen in these three patients. Patient 2 in this case series
had a better response to adalimumab therapy after loss of
efficacy of infliximab. Increasing the dosage of adalimu-
mab based on body surface area resulted in achievement
of good therapeutic activity in this patient. When treating
JIA, it is recommended that methotrexate is given with
adalimumab to optimize outcomes [25]. All three cases in
this report were receiving methotrexate at the time of ada-
limumab initiation.
Both methotrexate and adalimumab have corticosteroid-
sparing properties, and systemic corticosteroid therapy was
tapered and then withdrawn in all three cases. This was par-
ticularly notable in case 2, who had corticosteroid-dependent
disease. Withdrawal of corticosteroids in the youngest patient
(case 1) allowed catch-up growth to occur. The positive effect
of anti-TNF agents on disease control, and subsequently on
the growth of children with JIA, is a particularly attractive
feature of this approach to JIA management. Besides, in
case 1 patient, when treatment was initiated, use of adali-
mumab in the 2-year-old girl was off-label, because, at that
time, adalimumab was only approved in Italy for use in JIA
patients aged 4–17 years. But now, the authorization is ex-
tended for JIA patients over 2 years old.
Certainly, good results in terms of uveitis outcome were
seen in our three cases. A recent survey of US pediatric
rheumatologists on the treatment of patients with JIA re-
vealed that anti-TNF agents were used more often in those
with versus without co-morbid uveitis [40]. The co-
existence of JIA and uveitis was a contributing factor to
the decision to use adalimumab in case 3. This patient
was then able to stop methotrexate treatment, and ultim-
ately adalimumab, without relapse of either JIA or uveitis.
However, the follow-up period is not yet long enough to
make a definite statement about the ability of adalimumab
to induce long-term drug-free remission in this patient.
The other two patients achieved remission and continued
to receive adalimumab and methotrexate.
Our three patients tolerated adalimumab very well; no
clinical or laboratory adverse events were documented.
There are, however, well-known risks associated with anti-
TNF agents, including re-activation of latent tuberculosis
infection. This risk is managed by pre-treatment screening.
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have been treated with adalimumab, etanercept or inflixi-
mab [46]. However it is difficult to determine if this risk
is due to the biologic therapy or determined by the con-
comitant use of other immunosuppressive drugs, or by the
higher risk of malignancy in patients with JIA [47]. Such
data underscore the importance of large-scale, coordinated,
national and international pharmaco-vigilance programs for
better quantifying the risks and benefits of anti-TNF therapy
in children. Future analyses also need to take into account
the high cost of biological therapies, and therefore the cost-
effectiveness of this approach to treatment.
Conclusions
We have reported herein the case details of three chil-
dren with JIA and chronic uveitis treated with adalimu-
mab. These three children had good outcomes after the
addition of adalimumab to their treatment regimen. Our
data, from routine clinical practice, and in agreement
with clinical trials, further support the use of biologic
therapy for the management of JIA and uveitis, not re-
sponder to DMARDs, in children over two years of age.
Long-term follow-up, both from registries and clinical
trials, will help to further elucidate the ongoing efficacy
and tolerability of adalimumab, and other biologic drugs,
in these patients.
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